Literature DB >> 28569245

Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing.

Zhen-Fang DU1, Peng-Fei Li, Jian-Qiang Zhao, Zhi-Lie Cao, Feng Li, Ju-Ming Ma, Xiao-Ping Qi.   

Abstract

Approximately 98% of patients with multiple endocrine neoplasia type 2A (MEN 2A) have an identifiable RET mutation. Prophylactic or early total thyroidectomy or pheochromocytoma/parathyroid removal in patients can be preventative or curative and has become standard management. The general strategy for RET screening on family members at risk is to sequence the most commonly affected exons and, if negative, to extend sequencing to additional exons. However, different families with MEN 2A due to the same RET mutation often have significant variability in the clinical exhibition of disease and aggressiveness of the MTC, which implies additional genetic loci exsit beyond RET coding region. Whole genome sequencing (WGS) greatly expands the breadth of screening from genes associated with a particular disease to the whole genome and, potentially, all the information that the genome contains about diseases or traits. This is presumably due to additive effect of disease modifying factors. In this study, we performed WGS on a typical Chinese MEN 2A proband and identified the pathogenic RET p.C634R mutation. We also identified several neutral variants within RET and pheochromocytoma-related genes. Moreover, we found several interesting structural variants including genetic deletions (RSPO1, OVCH2 and AP3S1, etc.) and fusion transcripts (FSIP1-BAZ2A, etc.).

Entities:  

Mesh:

Year:  2017        PMID: 28569245     DOI: 10.1007/s12038-017-9686-5

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  74 in total

1.  RET fusion as a novel driver of medullary thyroid carcinoma.

Authors:  Elizabeth G Grubbs; Patrick Kwok-Shing Ng; Jacquelin Bui; Naifa L Busaidy; Ken Chen; Jeffrey E Lee; Xinyan Lu; Hengyu Lu; Funda Meric-Bernstam; Gordon B Mills; Gary Palmer; Nancy D Perrier; Kenneth L Scott; Kenna R Shaw; Steven G Waguespack; Michelle D Williams; Roman Yelensky; Gilbert J Cote
Journal:  J Clin Endocrinol Metab       Date:  2014-12-29       Impact factor: 5.958

2.  Activation of a novel human transforming gene, ret, by DNA rearrangement.

Authors:  M Takahashi; J Ritz; G M Cooper
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

4.  The involvement of the RET variant G691S in medullary thyroid carcinoma: conflicting results of meta-analyses need to be reconciled.

Authors:  Francesca Lantieri; Francesco Caroli; Isabella Ceccherini; Paola Griseri
Journal:  Int J Cancer       Date:  2013-04-22       Impact factor: 7.396

5.  Role of RET genetic variants in MEN2-associated pheochromocytoma.

Authors:  Débora Rodrigues Siqueira; Lucieli Ceolin; Carla Vaz Ferreira; Mírian Romitti; Silvana Cavalcante Maia; Léa Maria Zanini Maciel; Ana Luiza Maia
Journal:  Eur J Endocrinol       Date:  2014-03-10       Impact factor: 6.664

6.  High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients.

Authors:  Tsuneo Imai; Shinya Uchino; Takahiro Okamoto; Shinichi Suzuki; Shinji Kosugi; Toyone Kikumori; Akihiro Sakurai
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

7.  RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.

Authors:  Laura Fugazzola; Marina Muzza; Caterina Mian; Daniela Cordella; Susi Barollo; Luisella Alberti; Valentina Cirello; Davide Dazzi; Maria Elisa Girelli; Giuseppe Opocher; Paolo Beck-Peccoz; Luca Persani
Journal:  Clin Endocrinol (Oxf)       Date:  2008-02-11       Impact factor: 3.478

8.  Clinical diagnosis by whole-genome sequencing of a prenatal sample.

Authors:  Michael E Talkowski; Zehra Ordulu; Vamsee Pillalamarri; Carol B Benson; Ian Blumenthal; Susan Connolly; Carrie Hanscom; Naveed Hussain; Shahrin Pereira; Jonathan Picker; Jill A Rosenfeld; Lisa G Shaffer; Louise E Wilkins-Haug; James F Gusella; Cynthia C Morton
Journal:  N Engl J Med       Date:  2012-12-06       Impact factor: 91.245

9.  ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner.

Authors:  Huai-Xiang Hao; Yang Xie; Yue Zhang; Olga Charlat; Emma Oster; Monika Avello; Hong Lei; Craig Mickanin; Dong Liu; Heinz Ruffner; Xiaohong Mao; Qicheng Ma; Raffaella Zamponi; Tewis Bouwmeester; Peter M Finan; Marc W Kirschner; Jeffery A Porter; Fabrizio C Serluca; Feng Cong
Journal:  Nature       Date:  2012-04-29       Impact factor: 49.962

10.  Genome-wide analysis of noncoding regulatory mutations in cancer.

Authors:  Nils Weinhold; Anders Jacobsen; Nikolaus Schultz; Chris Sander; William Lee
Journal:  Nat Genet       Date:  2014-09-28       Impact factor: 38.330

View more
  2 in total

Review 1.  5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.

Authors:  Shu-Yuan Li; Yi-Qiang Ding; You-Liang Si; Mu-Jin Ye; Chen-Ming Xu; Xiao-Ping Qi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-18       Impact factor: 5.555

2.  Variability in Medullary Thyroid Carcinoma in RET L790F Carriers: A Case Comparison Study of Index Patients.

Authors:  Jes Sloth Mathiesen; Søren Grønlund Nielsen; Åse Krogh Rasmussen; Katalin Kiss; Karin Wadt; Anne Pernille Hermann; Morten Frost Nielsen; Stine Rosenkilde Larsen; Klaus Brusgaard; Anja Lisbeth Frederiksen; Christian Godballe; Maria Rossing
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-28       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.